AB0894 OBSERVANCE OF ZOLEDRONIC ACID INFUSION. A RETROSPECTIVE 3 YEARS STUDY

J. Zalc1, G. Camille1, B. Lisa1, J. Chioé1, B. Frédéric1, HIA Bégin, Saint Mandé, France

Background: Osteoporosis is a public health issue. Lack of therapeutic compliance is often a problem in the treatment of osteoporosis, with potentially dramatic consequences. No studies have evaluated the observance of zoledronic acid infusion after 3 years, the time of the therapeutic reassessment.

Objectives: The main objective of assessing the level of compliance was to evaluate the level of zoledronic acid infusion adherence at 1, 2 and 3 years periods, in a cohort of osteoporotic patients on discharge from Bégin hospital, following treatment for fracture caused by low-energy trauma. The first infusion was prescribed by rheumatologists, with the following infusions to be prescribed by general practitioners.

Methods: We performed a retrospective observational study initially conducted by written and telephone questionnaires on a population of patients hospitalized in the rheumatology department of HIA Bégin for an osteoporotic fracture. Data was collected between July 2015 and December 2018. A first letter, containing a stamped addressed envelope to the Bégin hospital for ease of reply, was sent to the patients selected for the study. The protocol had to be modified following a very low response rate, unaided by bad quality addresses. We then tried to contact the patients by phone 3 times and, if unable to reach them, we called their general practitioners on 3 occasions.

Results: 94 patients were initially selected. Every year, we retained within the study patients who had followed their annual zoledronic acid infusion protocol. Taking into account all 94 patients, adherence level for the first infusion was 41.4%, down to 29.7% for the second infusion and down to 12.8% for the third infusion. For those who had the first infusion performed, adherence level for the second infusion was 71.8%, down to 30.8% for the third infusion.

Conclusion: The observance and follow-up of zoledronic acid infusion in France by general practitioners is not adequate. Follow-up measures on an annual basis by the rheumatologist could significantly improve adherence.

References:

Acknowledgments: None

Disclosure of Interests: None declared

DO: 10.1136/annrheumdis-2020-eular.6267

AB0895 RELATIONSHIP BETWEEN BONE MINERAL DENSITY, INFLAMMATORY ACTIVITY AND AUTOIMMUNITY IN A COHORT OF EARLY RHEUMATOID ARTHRITIS PATIENTS

S. García Carazo1, D. Peiteado2, A. Villalba1, L. Nuño1, M. Díaz2, A. Balsa1, P. Agudo1, Hospital La Paz, Rheumatology, Madrid, Spain; 2Hospital La Paz, Rheumatology, Madrid, Spain; 3Hospital La Paz, Biostatistics, Madrid, Spain

Background: The etiology of bone loss in Rheumatoid Arthritis (RA) is multifactorial and systemic inflammation plays a relevant role. Recently, a relationship between autoimmunity and bone mineral density (BMD) has been described in patients with RA.

Objectives: To study BMD and biochemical parameters of bone metabolism in a cohort of patients with early rheumatoid arthritis, and assess the relationship between them and autoimmunity and other markers of inflammation.

Methods: A prospective longitudinal study was performed. 128 patients from an early Rheumatoid Arthritis Unit (ERAU) were included. All of them fulfilled ACR 2010 classification criteria for RA. Demographic, clinical, biochemical, immunological, radiological and densitometric data, and also inflammatory activity index DAS 28, HAQ functional index, were collected. Any value >20 IU/mL for RF and >30 UI/mL for ACYA was defined as positive.

Results: Between January 2009 and June 2017, 801 patients were evaluated in our ERAU. After two years of follow-up, the most frequently diagnostic profiles were: Early RA 221 (27.6%), Undifferentiated Arthritis 97 (12.1%), Psoriatic Arthritis 62 (7.7%), Spondyloarthritis 54 (6.7%) and autoimmune Diseases 28 (3.4%). From the 128 patients with early rheumatoid arthritis evaluated, 104 (81.9%) were ACYA positive and 98 (77.2%) FR positive. The mean BMD in the total column was 0.96 ±0.14 g/cm2 and in the femoral neck was 0.76 ±0.12 g/cm2. No correlation of BMD with autoimmunity markers was found in either of the two locations studied, while a negative relationship between BMD and the PCR inflammation marker (BMD femoral neck: rho=-0.203, p = 0.027 and BMD lumbar spine rho =-0.27, p = 0.003) was found. The BMD did not correlate with DAS28 nor the HAQ index.

Conclusion: The BMD in patients with early rheumatoid arthritis of our cohort correlates with the PCR inflammation marker. Unlike other studies, shows in our cohort, serological autoimmunity factors do not have shown to have an independent effect on BMD.

References:

Disclosure of Interests: None declared

DO: 10.1136/annrheumdis-2020-eular.4841

AB0896 EFFECTIVENESS OF SACROPLASTY IN THE MANAGEMENT OF OSTEOPORTIC SACRAL FRACTURE IN ELDERLY PATIENTS

S. Hecquet1, F. Verhoeven1, S. Aubry2, C. Prati1, D. Wendling1, CHRU Jean Minjoz, Rheumatology, Besançon, France; 2CHRU Jean Minjoz, Radiology, Besançon, France

Background: Sacral fractures are a source of pain leading to loss of autonomy in elderly patients. Sacroplasty may be an effective alternative of conservative medical treatment.

Objectives: To evaluate the short-term analgesic effect of sacroplasty compared to conservative treatment in patients with osteoporotic sacral fractures.

Methods: This is a retrospective study of cases of osteoporotic sacral fractures treated with sacroplasty, compared with cases treated with conservative medical procedure over the same period. Outcome was evaluated by pain (Visual analogic scale) short-term (one month) evolution and side effects occurrence.

Results: From January 2009 to June 2019, eleven patients were treated with sacroplasty for osteoporotic fractures at the Besançon University Hospital Centre. These were compared to 12 patients with osteoporotic sacral fracture with exclusive medical management, as a control group. The two groups were similar in age, gender and pain level at baseline. The median VAS was 7/10 in both groups at baseline. In the sacroplasty group, a significant decrease of pain was observed over the first two weeks, with a tendency remaining at day 30. There were no significant differences in the conservative treatment group at one week (p=0.2), fourteen days (p=0.6) and thirty days (p=0.7) compared to basal assessment.

Conclusion: Overall, sacroplasty was effective in the short term without significant side effects and could be a good alternative to conservative treatment in elderly patients with osteoporotic sacral fractures.

References: